Login / Signup

Physiology-based pharmacokinetic modelling and experimental data suggest that rifabutin alters dolutegravir kinetics by both P-glycoprotein induction and concurrent inhibition.

Dirk TheileJulie NillesAndreas Daniel Meid
Published in: British journal of clinical pharmacology (2023)
Keyphrases
  • electronic health record
  • locally advanced
  • antiretroviral therapy
  • big data
  • hiv infected patients
  • squamous cell carcinoma
  • data analysis
  • radiation therapy
  • aqueous solution